PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.15%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-30.87%
G&A reduction while AGEN shows 7.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.35%
Operating expenses reduction while AGEN shows 7.00% growth. Joel Greenblatt would examine advantage.
-30.35%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-2.47%
Both companies reducing D&A. Martin Whitman would check industry patterns.
30.79%
EBITDA growth 50-75% of AGEN's 48.92%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
30.35%
Operating income growth 50-75% of AGEN's 46.34%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-41.49%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
30.26%
Similar pre-tax income growth to AGEN's 33.33%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
30.26%
Similar net income growth to AGEN's 33.91%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
30.58%
Similar EPS growth to AGEN's 35.10%. Walter Schloss would investigate industry trends.
33.88%
Similar diluted EPS growth to AGEN's 35.10%. Walter Schloss would investigate industry trends.
0.94%
Share count reduction exceeding 1.5x AGEN's 1.90%. David Dodd would verify capital allocation.
5.92%
Diluted share reduction below 50% of AGEN's 1.90%. Michael Burry would check for concerns.